Life Sciences

  • October 14, 2026

    Fox Rothschild Beats Daycare's Malicious Prosecution Suit

    A New Jersey state court dismissed an adult daycare company's suit against Fox Rothschild LLP and one of its attorneys related to their prosecution of a fraudulent loan lawsuit that led to a $65,000 sanction against the firm, according to a court order.

  • October 14, 2026

    Sanofi Agrees Not To Disparage Rival's Flu Vaccine

    European enforcers have accepted commitments from Sanofi over concerns that it blocked competition from a rival flu vaccine for vulnerable patients by making disparaging statements to healthcare professionals in Germany and France.

  • October 13, 2026

    Liquidia Settles United Therapeutics Suits With $380.7M Deal

    Liquidia will pay out $380.7 million as part of a settlement agreement with United Therapeutics Corp. that resolves six lawsuits between the pharmaceutical companies, Liquidia announced Tuesday, saying patients will continue to have access to its Yutrepia lung disease treatment that was central to litigation.

  • October 13, 2026

    Skadden Adds 5 DLA Piper Mass Torts Attys To Chicago Office

    Skadden Arps Slate Meagher & Flom LLP continues to grow its mass torts and products liability litigation offerings in its Chicago office with the addition of five veteran litigators from DLA Piper, the firm announced on Tuesday.

  • October 13, 2026

    Biotech Co.'s Egg Protein Patent Case Flops In Del. Court

    A Delaware federal judge found cracks in a biotechnology company's jurisdictional arguments in a case it brought seeking a declaration that it wasn't infringing a rival's patent covering animal-free egg protein, ruling Friday there was no imminent controversy between the companies when the lawsuit was filed.

  • October 13, 2026

    FTC Wants Shkreli Sanctioned Over Pharma Industry Ban

    The Federal Trade Commission and seven states asked a New York federal judge Tuesday to hold Martin Shkreli in contempt for violating a court order banning him from the pharmaceutical industry by trading in industry stocks and broadcasting opinions about the business since he was released from prison in 2022.

  • October 13, 2026

    Corcept Looks To End Teva's Mifepristone Antitrust Case

    Corcept Therapeutics told a California federal court there's no evidence that it blocked generic competition for its cortisol disorder treatment Korlym, urging the court to toss an antitrust case from Teva Pharmaceuticals ahead of trial.

  • October 13, 2026

    Fed. Circ. Backs L'Oreal's Alice Win On Face Analysis Patent

    The Federal Circuit on Tuesday issued a one-word order affirming a California federal court's invalidation of a facial measurement and analysis patent that had been asserted against the cosmetic giant L'Oreal USA Inc.

  • October 13, 2026

    Judge Finds Cyanide Antidote Generic Infringes IP After Trial

    A Delaware federal judge ruled Tuesday that a generic version of a cyanide antidote was infringing three patents asserted by Hope Medical Enterprises after a bench trial where Accord Healthcare Inc. claimed its product did not infringe and that the patents were invalid.

  • October 13, 2026

    Groups Ask Justices To Hear Apple's ITC Industry Rule Fight

    The Federal Circuit wrongly continued the degradation of the U.S. International Trade Commission's domestic industry requirement in patent disputes by sustaining a decision that Apple Watches infringe Masimo Corp.'s patents, groups supporting Apple's petition told the U.S. Supreme Court on Tuesday.

  • October 13, 2026

    Jones Day, Morgan Lewis Guide $2.1B Steris-Xodus Deal

    Steris PLC has agreed to acquire specialty surgical products business Xodus Medical Inc. and some affiliates for $2.1 billion, with Jones Day advising Steris and Morgan Lewis & Bockius LLP representing Xodus.

  • October 13, 2026

    Troutman Grows Life Sciences Litigation Group In Philly, NY

    A pair of attorneys specializing in healthcare and life sciences litigation recently moved their practices to Troutman Pepper Locke LLP's offices in Philadelphia and New York City.

  • October 13, 2026

    1st Circ. Revives Amgen Migraine Drug Risk Label Suit

    A mother in Massachusetts is entitled to pursue a new theory of liability against drugmaker Amgen Inc. over the death of her 25-year-old son after he took the company's then-recently approved migraine medication Aimovig in 2018, the First Circuit has found.

  • October 13, 2026

    Haynes Boone Launches In San Diego For 4th Calif. Location

    Haynes Boone has opened its first San Diego office to deepen its life sciences, healthcare and technology capabilities and has selected a co-chair of its biotechnology practice to lead its fourth workplace in California.

  • October 13, 2026

    Dentons Adds K&L Gates Lawyer To Healthcare Practice In DC

    Dentons has hired a former K&L Gates LLP counsel as a partner in its Washington, D.C., office, where he will advise pharmaceutical, biotechnology and medical device companies on a range of matters related to regulatory and transactional oversight, the firm announced.

  • October 13, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week saw stockholders challenge Nvidia Corp.'s roughly $20 billion deal with artificial intelligence chipmaker Groq Inc., Hertz Global Holdings Inc.'s electric vehicle strategy and more than $1.5 billion in Humana Inc. stock buybacks.

  • October 09, 2026

    TRex Bio Leads 2 Drugmakers Pricing IPOs Totaling $162M

    Two clinical-stage biotechnology firms, TRex Bio and Retension Pharmaceuticals, hit the public markets on Friday after raising a combined $162 million in their initial public offerings.

  • October 09, 2026

    Gene Therapy Patent Suit Against Sarepta Comes To Close

    Sarepta Therapeutics Inc. no longer has to face a lawsuit accusing it of infringing a University of Pennsylvania gene therapy patent licensed by clinical-stage biotechnology company Regenxbio Inc. after the parties told a Delaware federal judge they agreed to end the case.

  • October 09, 2026

    Can Trade Secret Law Protect Indigenous Knowledge?

    As the U.S. and other countries struggle to agree on new international protections for Indigenous knowledge, trade secret law is drawing renewed attention as a possible solution for material that communities actually keep confidential.

  • October 09, 2026

    Woman Says Emory Healthcare's Inaction Led To Son's Death

    A Georgia woman sued Emory University and Emory Healthcare Inc. in state court, alleging they refused repeated requests to check on her son, who was later found unresponsive in a hospital parking deck and died of an accidental fentanyl overdose.

  • October 09, 2026

    'A Moral Hazard': Kalshi Drug Trial Bets Spark Ethical Qualms

    Kalshi Inc. opening prediction markets for clinical drug trials has raised a host of compliance concerns for attorneys, including the risk of insider trading among the wide swaths of stakeholders in the know about the trials, as well as the danger of compromising the trials themselves.

  • October 09, 2026

    Vape Cos. FDA Suit On Hold As Agency Reviews Policy

    A Texas federal court has granted a joint motion to stay litigation by an Altria Group Inc. vape subsidiary challenging the U.S. Food and Drug Administration's premarket authorization rule, pausing proceedings while the FDA pursues rulemaking to replace the challenged framework.

  • October 09, 2026

    ERISA Recap: 6 Notable Decisions From September

    The Tenth and Seventh circuits issued published opinions in two union retirement disputes, while the Sixth Circuit found that the Commonwealth of Kentucky's lawsuit against pharmacy benefit managers does not belong in state court, citing colorable federal preemption arguments. Here's more on those decisions and three other notable rulings involving the Employee Retirement Income Security Act that came down in September.

  • October 09, 2026

    Squires Grants 4 PTAB Petitions, Rejects 3 In New Drop

    U.S. Patent and Trademark Office Director John Squires has instituted four new America Invents Act reviews at the Patent Trial and Appeal Board and turned down three in his newest mass order.

  • October 09, 2026

    Eli Lilly Lobs 4 Suits Alleging Illegal Weight Loss Drug Sales

    Eli Lilly and Co. has sued an Arizona weight loss clinic and three online sellers, alleging they are illegally selling products containing the pharmaceutical giant's investigational molecule that has not yet been approved for use in any drug, endangering consumers in a mockery of safety guidelines.

Expert Analysis

  • Why Vaccine Court Inoculates Drug Makers Against Litigation

    Author Photo

    Most claimants alleging injuries from routine childhood vaccines must complete an administrative compensation proceeding before they can sue in civil court — and recent legislative efforts aimed at weakening vaccine manufacturers' legal protections do not account for the important reasons the existing framework was put in place, say attorneys at Goldman Ismail.

  • What Lawyers Should Know Before Accepting Crypto Payment

    Author Photo

    As clients increasingly request to pay legal fees, retainers and escrow funds using cryptocurrency, lawyers should consider how only a handful of state bar authorities have addressed the issue with varying ethics opinions, as well as the related questions that no authority has yet answered, says attorney Felix Shipkevich.

  • What To Know As State 'Neural Data' Privacy Laws Emerge

    Author Photo

    Attorneys at Goodwin discuss new state laws aimed at regulating consumer data generated from nervous system activity, explain why neurotechnology is attracting state and federal legislators’ attention, and highlight the compliance obligations that industry players should address now.

  • Data Sale In Spirit Bankruptcy Raises Novel Privacy Risks

    Author Photo

    Spirit Airlines' planned sale of deidentified business data to Google for artificial intelligence training exposes gaps in the Bankruptcy Code's privacy guardrails, particularly for employee information, say attorneys at Patterson Belknap.

  • IDScan Data Breach Puts Spotlight On Vendor Oversight

    Author Photo

    A recently reported breach that exposed millions of identification documents held by IDScan.net highlights the liability risks for businesses that contract with third-party identity processors, and emphasizes the importance of auditing vendors' data retention practices, say attorneys at Tucker Ellis.

  • Series

    Mentalism Makes Me A Better Lawyer

    Author Photo

    Convincing strangers I can read their minds may seem like an unusual second career for a legal practitioner, but both disciplines share several important requirements, including trust and preparation, says Warren Biro at Manatt.

  • Why And How To Build A Neurodiversity-Informed Practice

    Author Photo

    By better understanding neurodiversity and implementing simple accommodations for clients with autism, ADHD or learning differences, attorneys can build stronger relationships with those who may otherwise struggle to obtain and benefit from legal services, while developing good habits that will benefit everyone they represent, says Ting Cheung at Sanford Heisler.

  • Opinion

    PTAB Panels Should Revamp Their IPR Merits Decisions

    Author Photo

    In light of U.S. Patent and Trademark Office Director John Squires' recent announcement about returning merits institution determinations to the Patent Trial and Appeal Board, the implementing framework should strengthen PTAB panels' responsibility for the benefit of both petitioners and patent owners, says Brandon Theiss at AddyHart.

  • Patent Eligibility Bulletin: Claim Solutions, Not Results

    Author Photo

    In the third quarter of the year, two Federal Circuit decisions illustrated that claims sharing the same disclosure can fall on opposite sides of the patent eligibility line, depending on the specific nuances of tech patents' claims, says Reilley Keane at Banner Witcoff.

  • Abbott FCA Deal Shows Enforcement Adequacy Quandaries

    Author Photo

    Abbott Laboratories’ recent False Claims Act resolution illustrates several tricky questions that both prosecutors and defense counsel must address when weighing whether a civil enforcement action alone adequately addresses allegedly wrongful conduct, says James Koukios at MoFo.

  • New DNA Screening Standard Has No Clear Playbook

    Author Photo

    Although the government has not yet released promised guidance intended to support its new standards for screening mail-order DNA, companies should not read this as a reprieve from the Oct. 13 compliance deadline because the delay shifts enforcement risk to statutes that need no new authority, including false statements, the False Claims Act and fraud, says Ashwin Ram at Buchalter.

  • Series

    Mich. Banking Brief: All The Notable Legal Updates In Q3

    Author Photo

    We are at an inflection point for Michigan financial services law, with a state Supreme Court decision recently overruling more than 25 years of precedent on the Michigan Consumer Protection Act, and pending legislation that could significantly shift the regulatory landscape, say attorneys and advisers at Dykema.

  • Testing AI's Promise For Large-Scale Document Review

    Author Photo

    Our document-review comparison of attorneys' responsiveness and issue coding decisions versus predictions generated by artificial intelligence across 1,600 documents suggests that these tools can offer a reasonable and reliable basis for improved discovery workflows, provided lawyers understand where guardrails are needed, say attorneys at Redgrave.

  • AG Watch: Va. Vape Product Regulations Enter A New Phase

    Author Photo

    Virginia's new vape enforcement framework carries important implications related to product eligibility and certification requirements for businesses operating in the marketplace, representing the culmination of several years of legislative action, regulatory development, litigation and interagency planning, says Chuck Slemp at Cozen O'Connor.

  • Navigating A Key Inflection Point In Biosimilar Sector M&A

    Author Photo

    As biosimilar mergers and acquisitions gain notice amid U.S. Food and Drug Administration reforms, a maturing patent framework and a looming patent cliff, companies diversifying into the higher-growth biologics space should align their regulatory, intellectual property and transactional strategies, say attorneys at Skadden.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here